For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Mitomycin C in Combination with Vinorelbine in Anthracycline- and/or Taxane-Pretreated Patients with Metastatic Breast CancerSchippert C.a · Warm M.b · Blohmer J.-U.c · du Bois A.d · Lück H.-J.e
aKlinik für Frauenheilkunde und Geburtshilfe, Medizinische Hochschule Hannover, bBrustzentrum am Krankenhaus Köln-Holweide, Köln, cFrauenheilkunde und Geburtshilfe und Brustzentrum-City, St. Gertrauden Krankenhaus, Berlin, dKlinik für Gynäkologie & gynäkologische Onkologie, Kliniken Essen Mitte, Essen, eGynäkologisch-onkologische Praxis Hannover, Germany
Background: Patients with metastatic breast cancer (MBC) with disease progression after anthracycline-and/or taxane-containing therapy need an effective drug regimen with low toxicity. Mitomycin C (MMC) and vinorelbine (VNR) are suitable candidates for combination therapy in the second-/third-line treatment of MBC. This study evaluates the safety and efficacy of an MMC/VNR combination chemotherapy in pretreated patients with MBC. Patients and Methods: In a phase II trial, patients with anthracycline-and/or taxane-pretreated MBC were treated with MMC 8 mg/m2 (day 1) and VNR 25 mg/m2 (days 1 and 8) every 4 weeks for up to 6 cycles or until disease progression. Results: In 51 eligible patients, 13 (26%) partial remissions (PRs), 20 (39%) stable diseases (SDs) and 18 (35%) progressive diseases (PDs) were observed. The median progression-free survival (PFS) was 5.0 months. The main grade 3/4 toxicities were neutrocytopenia (41%), granulocytopenia (37%), and thrombocytopenia (4%). Other hematological and non-hematological toxicities were mostly mild. Conclusion: The combination of MMC and VNR is an effective and relatively well-tolerated regimen for anthracycline- and/or taxane-pretreated patients with MBC and is suitable for outpatient therapy.
© 2012 S. Karger AG, Basel